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ABSTRACT: Nanocrystalline hydroxyapatite (nanoHA) is the main hard
component of bone and has the potential to be used to promote
osseointegration of implants and to treat bone defects. Here, using active
pharmaceutical ingredients (APIs) such as ibuprofen, we report on the
prospects of combining nanoHA with biologically active compounds to improve
the clinical performance of these treatments. In this study, we designed and
investigated the possibility of API attachment to the surface of nanoHA crystals
via the formation of a hydrogen-bonded complex. The mechanistic studies of an
ibuprofen/nanoHA complex formation have been performed using a holistic
approach encompassing spectroscopic (Fourier transform infrared (FTIR) and
Raman) and X-ray diﬀraction techniques, as well as quantum chemistry calculations, while comparing the behavior of the
ibuprofen/nanoHA complex with that of a physical mixture of the two components. Whereas ibuprofen exists in dimeric form
both in solid and liquid state, our study showed that the formation of the ibuprofen/nanoHA complex most likely occurs via the
dissociation of the ibuprofen dimer into monomeric species promoted by ethanol, with subsequent attachment of a monomer to
the HA surface. An adsorption mode for this process is proposed; this includes hydrogen bonding of the hydroxyl group of
ibuprofen to the hydroxyl group of the apatite, together with the interaction of the ibuprofen carbonyl group to an HA Ca center.
Overall, this mechanistic study provides new insights into the molecular interactions between APIs and the surfaces of bioactive
inorganic solids and sheds light on the relationship between the noncovalent bonding and drug release properties.
1. INTRODUCTION
Hydroxyapatite (abbreviated as HA), with its chemical formula
Ca10(PO4)6(OH)2, is a major inorganic component of bone
and, along with collagen ﬁbrils, it accounts for up to 65% of the
hard tissue of vertebrates. Bone-derived hydroxyapatite is
nanosized, nonstoichiometric, calcium-deﬁcient carbonated
ceramic material with low crystallinity.1 Synthetic poorly
crystalline nanoscale HA that mimics the composition of
natural bone has long been employed in orthopedics for the
treatment of bone defects resulting from trauma or surgery,
because it possesses excellent biocompatibility and osteocon-
ductivity properties,2 thus showing a great potential for use in
bone tissue engineering3 and implant osseointegration,4 as well
as being a potential gene5 or drug carrier.6,7
Drug delivery systems based on ceramics,8,9 polymers,10 or
hydrogels11 have received an enhanced interest in the last
decades. HA-based ceramic drug carriers, in turn, have been
particularly studied as prospective drug delivery systems for the
treatment of bone infection,12,13 as well as arthritis.14
Osteoarthritis and rheumatoid arthritis, despite having diﬀerent
causes behind the diseases, share similar symptoms of chronic
pain due to associated peripheral inﬂammation. Both are
considered to be important public health concerns,15 with
osteoarthritis being the most common cause for total hip or
knee replacement. The results of total arthroplasty in arthritic
patients shows that HA-coated prostheses have excellent
medium-term eﬃcacy,16 promoting osseointegration and, in
turn, opening up the prospects of using bioactive ceramics as
drug carriers for the treatment of bone diseases.
One of the most common analgesic anti-inﬂammatory
nonsteroidal drugs used for the relief of pain symptoms in
arthritic patients is ibuprofen.17 Ibuprofen, or 2-(4-isobutyl-
phenyl) propanoic acid (Figure 1a), exists as a cyclic hydrogen-
bonded dimer in a solid state (Figure 1b),18 and its anti-
inﬂammatory and analgesic activity is assigned to the
monocarboxyl groups of an ibuprofen monomer.19 Based on
this, it is beneﬁcial to introduce ibuprofen into the body as a
monomer, for instance as a sodium salt,20 for an improved
performance due to a higher drug solubility.
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Several attempts have been made to combine HA and
ibuprofen for treating bone-associated diseases, possibly in a
monomeric state to achieve the desired drug dissolution
rates.21,22 These studies attempt to relate the prolonged
retention times and drug release either with the geometry of
the materials23 or with the porosity of ceramics,24 in
combination with hydrogen bonding eﬀects between HA and
ibuprofen monomer. While the majority of studies produced
materials using a trial-and-error approach to determine the best
possible combination of an API and an excipient, they did not
focus on the mechanism of the API adsorption and release, but
rather on the ﬁnal formulation with certain characteristics.
However, to the best of our knowledge, there are currently no
insights into the physical chemistry behind the ibuprofen
loading onto the surface of hydroxyapatite and its release. In
this paper, we report, for the ﬁrst time, on mechanistic studies
that describe the adsorption of ibuprofen on the surface of HA
and propose a possible mechanism for the interaction of
ibuprofen and hydroxyapatite at the molecular level. The
understanding of the surface properties of ceramics and its
inﬂuence on the API dissolution rates may provide a useful
conceptual platform for the rational development and design of
formulations with the desired controlled and sustained drug
release.
2. MATERIALS AND METHODS
2.1. Nanohydroxyapatite Preparation. Nanohydroxyapatite was
prepared as reported in ref 25 and references therein. In brief, calcium
hydroxide (Ca(OH)2) (3.704 g, assay ≥96%, Sigma−Aldrich) and
phosphoric acid (H3PO4) (3.459 g, 85 wt % in water, Sigma−Aldrich)
were dissolved in 100 mL of deionized water each. The solution of
phosphoric acid was fed into the solution of calcium hydroxide at
room temperature using a peristaltic pump at a rate of 3 mL min−1.
The resulting slurry was left under constant stirring for 2 h for aging
and left overnight for settling. The top aqueous layer was then
removed and the suspension was dried at 60 °C and subsequently
ground using an agate mortar and pestle to form a powder. A portion
of the powder was calcined for 2 h in a furnace at 1000 °C (with a
heating rate of 10 °C min−1) in order to evaluate its thermal stability.
2.2. Ibuprofen/Nanohydroxyapatite Complex Synthesis. To
prepare an ibuprofen/HA complex, the following procedure was
employed. Ibuprofen (200 mg, grade 70 UPS/EP, Albemarle) was
dissolved in anhydrous ethanol (5 mL, absolute 99%+, Fisher) in a 19/
26 joint 100 mL round-bottom ﬂask. A sample of dried as-prepared
nanoHA (800 mg) was added to the solution and stirred in a Buchi
Rotavapor at 30 °C and 350 mbar for 1 h at a speed of 60 rpm. The
temperature then was increased to 45 °C and the pressure was reduced
to 175 mbar to reach the condition of a very viscous paste (to avoid
complete evaporation of ethanol). The reproducibility of the method
was evaluated using ATR-FTIR experiments for each sample to
conﬁrm the presence of monomeric, dimeric, and attached species
(where applicable). The reason behind opting for the 20 wt % loading
is explained in the Supporting Information (Figure S1). An aliquot of
the paste was used for in situ and ex situ spectroscopic studies, whereas
the remaining part was dried at room temperature for 24 h and used
for morphological examination.
2.3. Materials Characterization. Fourier transform infrared
(FTIR) spectra were acquired using a ThermoFisher Nicolet iS50
FTIR spectrophotometer that was equipped with a single reﬂection
diamond attenuated total reﬂection (ATR) module. Spectra were
recorded in the absorbance mode from 4000 cm−1 to 375 cm−1 at 1
cm−1 resolution, averaging 64 scans.
Powder X-ray diﬀraction (PXRD) patterns were acquired using a
Bruker D8 Avance diﬀractometer operating at 40 kV and 40 mA with
Cu Kα radiation. In order to minimize preferred orientation of
crystallites within specimens, PXRD data were collected in Debye−
Scherrer mode for ibuprofen-containing samples mounted in silica
glass capillaries using a PANalytical X’Pert3 powder diﬀractometer with
Cu Kα radiation, operating at 45 kV, 40 mA, and a Medipix3 Pixcel1D
detector. The samples were analyzed in the range of either 20°−60° 2θ
for nanoHA characterization or from 0°−80° 2θ for ibuprofen and
ibuprofen/HA complexes. Analysis of the obtained patterns was
carried out using X’Pert HighScore Plus software, and stripping of the
Kα2 component was carried out when appropriate. Crystallite sizes for
the HA were determined using the Scherrer equation,26 and XRPD
patterns were compared with entries of the International Centre for
Diﬀraction Data (ICDD) Powder Diﬀraction File (PDF).
Raman spectra were obtained using a home-built Raman
spectrometer, as described in ref 27, but with the following
modiﬁcations: using a frequency doubled Nd:YAG laser, 532.2 nm,
20 mW (Lasos, GL3dT) and a monochromator (Andor SR-163)
equipped with 1200 l/mm grating, 500 nm blaze, and cooled CCD
camera (Andor i-Dus, −60 °C). Eﬀective slit width is given by a 100
μm core diameter ﬁber. Wavenumber calibration was performed using
Ne emission lines and known benzene Raman transitions (NIST
database28). Experimental resolution was ∼8 cm−1, and the full width
at half-maximum (fwhm) was ∼1700 cm−1. With regard to Raman
shifts, the Raman peak position accuracy was estimated to be ±3 cm−1.
Scanning electron microscopy (SEM) images were recorded using a
Hitachi Model TM3000 electron microscope operating at 15 kV. All
samples were sputtered with gold prior to analysis.
Dissolution experiments were performed using a UPS II type
Labindia dissolution tester (Model Labin-09, India). Ibuprofen/HA
complex, physical mixture of ibuprofen and HA or raw ibuprofen
powders were placed at the bottom of the dissolution vessel (at least
four repeats) containing 900 mL phosphate buﬀer (pH 7.2)
maintained at 37 ± 0.5 °C and stirred with a paddle at 50 rpm.
Samples were collected periodically and further ﬁltered. Quantiﬁcation
of ibuprofen was performed spectrophotometrically at a ﬁxed
wavelength of 221 nm, using a Jasco Model V630 spectrophotometer.
1H NMR experiments were recorded at 400 MHz using a Bruker
Avance III 400 spectrometer. Measurements were collected at room
temperature for solutions of ibuprofen in CDCl3 or CD3CD2OD
(Sigma−Aldrich). Fitting of the NMR peaks was carried out using
Bruker TopSpin 3.2 software, and data analysis was carried out by
using a successive approximation method based on a ﬁxed-point
iteration algorithm.
2.4. Computational Studies. Quantum chemical calculations
were performed using Gaussian 09, version D.01.29 A density
functional theory (DFT)30 method using the B3LYP functional and
a 6-311G(d,p) basis set (Pople triple split valence Gaussian basis
functions with added polarization functions) for all atoms have been
employed.31 The nature of stationary states (minimum structures) was
conﬁrmed by frequency calculations. Stabilization energies of the
complexes were obtained by subtraction from energetic values of
isolated species and considering zero-point-energy (ZPE) correc-
Figure 1. Structures of (a) ibuprofen monomer, 2-(4-isobutylphenyl)
propanoic acid, and (b) dimer of ibuprofen highlighting the hydrogen
bond between carboxyl groups.
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tions32 for all of the molecular structures. Calculated wavenumbers to
compare with experimental infrared spectra were obtained from
harmonic vibrational frequencies using the B3LYP density functional
method with the 6-311G(d,p) basis set by introducing a scaling factor
of 0.9616.33
3. RESULTS AND DISCUSSION
3.1. NanoHA Characterization. The inorganic part of
bone is mainly made of a nanodimensional nonstoichiometric
poorly crystalline HA phase with small inclusions of carbonate.1
Several characterization techniques were employed to verify
whether the synthesized ceramics mimic the bone composition.
Figure S2 in the Supporting Information shows the XRD
pattern of both as-prepared and calcined HA. It can be seen
that the raw material (Figure S2a) is made solely of HA phase
that fully matches JCPDS File No. 9-432 (for a visualization of
its unit cell, see Figure S3 in the Supporting Information). The
broad reﬂection peaks on the XRD patterns in the region
between 20° and 50° 2θ are usually characteristic of either
partially amorphous or nanoparticulate material. Interestingly,
Figure S2b reveals that the composition of the materials has
changed after calcination. Besides the main phase of HA,
another phase of tricalcium phosphate, or TCP (JCPDS File
No. 9-169), appeared. This is caused by the decomposition of
the nonstoichiometric HA into β-calcium phosphate.34
Crystallinity calculations, in turn, showed that the raw, or as-
prepared HA, is composed of ca. 35% crystalline component,
whereas the crystallinity of the calcined HA expectedly reached
ca. 96% after a prolonged heat treatment (Table 1).
According to the Rietveld reﬁnement results for the lattice
parameters, the calculated unit cell of the raw HA was 531.4 ±
1.1 Å3, whereas for the calcined material, it was 526.5 ± 1.1 Å3,
while the proportion of the second phase of tricalcium
phosphate (TCP) was 23 wt %. The Scherrer equation26
allowed us to evaluate the crystallite size, which appeared to be
13 nm for raw HA and 79 nm for calcined HA. Decomposition
of HA into TCP after thermal treatment and reduction of the
unit cell volume is indirect evidence of its nonstoichiometry,
whereas its particle (crystallite) size lies within a nanometer
range, thus proving that the HA used for this study is indeed a
nonstoichiometric nanosized material with poor crystallinity.
To further prove its similarity to the HA in the bone, we used
an attenuated total reﬂectance (ATR) FTIR technique, since
XRD alone, being a bulk method, cannot reveal all of the details
of the HA composition, especially for the layers of solid close to
its surface. ATR-FTIR is a spectroscopic technique where an IR
beam is directed at a solid sample and is further reﬂected to a
detector.35 An important aspect of this method is that this
technique is often regarded as a “surface” method with a
penetration depth in the range of 0.5−3 μm.36 That is, the
method is a surface technique when compared to XRD, but not
a pure surface analysis method like X-ray photoelectron
spectroscopy, which probes 0.5−10 nm instead. However,
considering that (i) our HA is present in the form of
agglomerates ranging from 20 μm to 200 μm and (ii) ibuprofen
is also in a similar range (vide inf ra; see Figure 3), we can
ascribe the use of ATR-FTIR as a surface method, but with a
large penetration depth. This particular aspect of the technique
will be important also for the investigation of the mechanism of
adsorption of ibuprofen to the HA surface (see section 3.4.4).
An ATR-FTIR spectrum of raw hydroxyapatite is reported in
Figure S4 in the Supporting Information. The main active
bands lie in the region of 1100−400 cm−1, with the typical
phosphate stretching bands lying in the range of 1200−900
cm−1, as well as at ∼600 cm−1, being in agreement with
previously published data, hydroxyl group vibrations are located
at 3571 and 632 cm−1.37−39 Minor carbonate substitution of B-
type (CO3
2− for PO4
3−) was also detected with the
corresponding peaks for bending and stretching modes at
870 cm−1 and 1600−1300 cm−1, respectively, thus suggesting
that the surface carbonate formation occurred during the
preparation, despite the fact that carbonate anions were not
deliberately introduced into the system. This is a known
phenomenon where CO2 capture from the atmosphere may
occur when one of the solutions has high pH values40 or a
strongly basic surface in the presence of moisture. Overall, the
presence of small amounts of carbonate groups on the surface
of HA is characteristic for the wet precipitation preparation
method. However, our results are slightly diﬀerent from
previously reported studies where it has been suggested that
A-type carbonate substitution (CO3
2− for OH−) occurs at
lower temperatures, whereas B-type substitution is a feature of
the materials prepared at elevated temperature ranges.25 We
observed only a slightly detectable A-type substitution with the
B-type dominating, thus suggesting that the material mostly
mimics the young bone tissue,41 as the ratio of A/B types is
age-dependent and also inﬂuences the HA crystallinity and
solubility.42
3.2. Ibuprofen/HA Complex Formation. In order to
prepare an ibuprofen−HA complex, we opted for dissolution of
the API in ethanol with subsequent solvent evaporation under
vacuum and deposition of ibuprofen onto the ceramic’s surface
while drying in a Rotavapor.43 The reason behind such a choice
is 2-fold. First, ethanol is a much more “green” solvent, with
minimal environmental impact in chemical production,
compared to the widely used hexane, yet it still allows
successful solubilization of ibuprofen. Second, the solvent
evaporation process allows us to control the API loading and
eliminates the need of postprocessing the API content
measurement (as in the case of immersion of HA into hexane
with dissolved ibuprofen21), since there is no API loss during
the preparation and the ibuprofen uptake is independent of the
porosity properties of the ceramic.
Table 1. Unit-Cell Parameters from Rietveld Reﬁnement and Crystallinity Evaluations of NanoHA As-Synthesized and Calcined
at 1000 °Ca
Unit-Cell Parameters (Å)
material a b c unit-cell volume, V (Å3) crystallite size (nm) crystallinity (%) HA phase purity (wt %)
HA raw 9.439 9.439 6.887 531.4 ± 1.1 13 35 100
HA calcined 9.403 9.403 6.876 526.5 ± 1.1 79 96 77b
aContraction of the unit cell upon calcination is observed as well as increase in crystallinity. A second phase, namely tri-calcium phosphate or TCP,
has also been detected after thermal treatment, showing non-stoichiometry of the as-prepared HA. b23 wt % attributed to the tricalcium phosphate
(JCPDS File No. 9-169).
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With the objective of evaluating the possibility of API
attachment to the surface of HA, we employed a wide variety of
methods. First, we wanted to assess the homogeneity of the
ibuprofen distribution on the surface of ceramics. Figure 2
shows the comparison of XRD patterns between as-prepared
HA (Figure 2a), pure ibuprofen from the supplier (Figure 2b),
ibuprofen recrystallized from ethanol using the method of
ibuprofen/HA complex preparation with the ceramic addition
step being omitted (Figure 2c), and the ibuprofen−
hydroxyapatite complex itself (Figure 2d).
As can be seen from the patterns, while both commercial and
ethanol recrystallized ibuprofen specimens are highly crystalline
(full match with the JCPDS database entry 32-1723), the
ibuprofen/HA complex does not exhibit any reﬂections
characteristic of ibuprofen but shows only broad reﬂections
of a poorly crystalline HA phase. The absence of ibuprofen
reﬂections on the XRD patterns in general can be explained by
any of the following reasons: (i) amorphous or low crystalline
component, (ii) particle size below 4−5 nm, and (iii) highly
dispersed thin layered structure. In our case, we can eliminate
the amorphous phase formation because, in the case of ethanol-
recrystallized ibuprofen, a highly crystalline material was
observed (Figure 2c); therefore, the most probable explanation
of the absence of the ibuprofen reﬂections in the ibuprofen/HA
complex pattern is the presence of a well dispersed thin layer of
ibuprofen or small particles.
SEM also revealed some interesting ﬁndings. Figure 3 shows
the micrographs of raw HA (Figure 3A), commercial ibuprofen
(Figure 3B), ibuprofen after ethanol recrystallization (Figure
3c), and ibuprofen/HA complex (Figure 3D).
It can be seen that raw HA consists of reasonably large
agglomerates of ca. 200 μm and some smaller clusters of 10−20
μm. Commercial ibuprofen showed rod-shaped particles of ca.
50−200 μm, whereas ethanol-recrystallized ibuprofen particles
are randomly shaped with the average size ranging from 10 μm
to 250 μm. We do not exclude the possibility of the formation
of rod-shaped particles with larger dimensions during the
recrystallization of ibuprofen, as the recrystallized sample is
crushed in a mortar and pestle prior to analysis, and this may
not be a complete representation of the particle shape and size.
However, we need to compare the ethanol treated ibuprofen
specimen with the ibuprofen/HA complex that has also been
ground to reach a powder form, and we believe the comparison
Figure 2. PXRD patterns of (a) raw HA, (b) commercial, or as
received, ibuprofen from the supplier, (c) commercial ibuprofen
recrystallized in ethanol, (d) ibuprofen/hydroxyapatite (ibuprofen/
HA) complex. The pattern of ibuprofen/HA complex is similar to that
of pure HA, no peaks of ibuprofen detected, suggesting a thin layered
structure. Patterns (b) and (c) for crystalline ibuprofen have been
scaled down for better visualization purposes.
Figure 3. SEM micrographs of (A) raw HA, (B) commercial, or as-received, ibuprofen from the supplier, (C) commercial ibuprofen recrystallized in
ethanol, and (D) ibuprofen/hydroxyapatite (ibuprofen/HA) complex. Similar particle shapes and sizes were observed for as-prepared HA (panel (a)
and ibuprofen/HA complex (d).
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between two SEM micrographs for these materials is valid in
this case.
Another interesting feature observed during the SEM analysis
was specimen destruction under the electron beam (Figure S5
in the Supporting Information). Structural damage upon
irradiating the sample with the beam of electrons is a well-
known phenomenon and may happen not just with organic
samples44 but also with ceramics, although at much higher
accelerated voltages and current densities.45 We decided to
exploit this feature to try to visualize the presence of ibuprofen
in our ibuprofen/HA complex. In other words, if the ibuprofen
recrystallized in the presence of HA to form large clusters like it
does in the absence of ceramics (Figure 3C), ibuprofen
particles would be damaged upon prolonged (30 s or more)
exposure to the 15 kV electron beam. However, if the ibuprofen
forms a thin layer on the entire surface of the HA, it would be
much harder to detect electron beam damage upon exposure.
After careful inspection of the specimen of ibuprofen/HA
complex under SEM at diﬀerent magniﬁcations and various
irradiation times (Figure S5) we were not able to detect any
structural deformation. Thus, by using a “negative proof”
approach of deliberate prolonged irradiation of the specimen
with an electron beam and comparing it with bulk ibuprofen
behavior in SEM under the same conditions, we demonstrated
that our material is indeed a thin layered structure. While bulk
ibuprofen was easily damaged by the beam, we did not ﬁnd any
areas of beam damage for the Ibu/HA samples, thus suggesting
that no large areas of ibuprofen clusters were formed during the
synthesis, and our material is most likely a homogeneous
mixture of ibuprofen and HA, with the former creating a thin
layer on the surface of HA. This observation is more indirect
evidence of a highly dispersed thin layer of API on the surface
of HA, rather than a biphasic space separated API−ceramic
system, thus complementing our earlier XRD ﬁndings.
Further insights into the complex formation can be obtained
using ATR-FTIR spectroscopy. Figure 4 shows the spectra of
ibuprofen/HA complex (spectrum in Figure 4a) and ethanol-
treated ibuprofen (spectrum in Figure 4b).
The majority of active bands are in the ranges of 1800−500
cm−1 and 3200−2400 cm−1, with the former assigned to
carbonyl group, tertiary and quaternary carbon atoms, and OH
bending vibrations, and latter to the C−H and C−C bond
stretching.46 Interestingly, overlapping of the two spectra (see
inset on Figure 4) clearly shows the shift of the ibuprofen C
O group stretching to the higher wavenumbers from 1707 cm−1
to 1717 cm−1. Similar shifts have been reported in the literature,
and they are usually explained, yet not proved, by the hydrogen
bonding between the hydroxyl group of HA and the carbonyl
group of ibuprofen. However, the degree of this deviation was
variable from study to study, ranging from 1720 cm−124 to 1547
cm−1.23 This large variability in literature data, as well as the
lack of direct evidence on the actual nature of molecular bond
interactions between ibuprofen and HA, prompted us to
investigate this issue in more detail.
3.3. Fourier Transform Infrared (FTIR) Studies of
Ibuprofen Monomer, Dimer, and Attached/Chemi-
sorbed Species. First, we decided to evaluate the behavior
of ibuprofen in ethanol solution. It is known that ibuprofen
exists in a hydrogen-bonded cyclic dimeric form that is stable in
both solid and liquid phases.18 We aimed to verify the
possibility of the existence of the ibuprofen monomer in the
ethanol solution as we employed this solvent for our studies.
To do so, we dissolved ibuprofen crystals in absolute ethanol
and deposited the resulting solution dropwise onto the ATR
crystal of the ATR−FTIR spectrometer and allowed it to dry
naturally, taking measurements at the beginning and end of the
experiment. Figure S6a in the Supporting Information shows
the IR spectrum at the zero time point measurement in the
presence of ethanol, whereas Figure S6b in the Supporting
Information shows the spectrum of ibuprofen after 4 h when
the ethanol had completely evaporated (as indicated by the
absence of ethanol’s most active bands at 880, 1046, and 1087
cm−1 and a broad band between 3600 and 3000 cm−1). What is
immediately apparent is the presence of a broad shoulder in the
region between 1760 and 1720 cm−1 in the spectrum
corresponding to the ibuprofen dissolved in ethanol (Figure
S6a). Deconvolution of this part of the spectrum (see inset in
Figure S6) allowed us to determine the peak position of a
second species, which appeared to be at ca. 1735 cm−1 and has
been assigned as the CO stretching vibration of monomer
ibuprofen aﬀected by hydrogen bonding with ethanol (further
conﬁrmed by the computational studies). Thus, we have proven
that ibuprofen may exist in both dimeric and monomeric forms
when ethanol is present in the system.
In order to provide semiquantitative information for the
amounts of monomer and dimer in solution that will be useful
for our data treatment for adsorbed species, the equilibrium
constant (Keq,D) for the process 2 ×M→ D was determined by
NMR, where M represents the monomer and D the dimer.
This determination was carried out in chloroform to minimize
the proton exchange and, in turn, line broadening, and,
therefore, the visibility of the proton of the COOH group of
ibuprofen involved in the dimer formation. As monomer and
dimer are in fast exchange regime, the signal of the proton for
the COOH group will appear as a single broad peak. Its
position is dependent on the amount of monomer and dimer
by the correlation: δm = δMPM + δDPD,
47 where δm represents
the measured average position of the proton involved in the
monomer/dimer equilibrium, δM is an extrapolated position for
the sole monomer, δD an extrapolate peak position for the
dimer, and PM and PD the populations of monomer and dimer
Figure 4. ATR-FTIR spectra of ibuprofen/HA complex (spectrum in
Figure 4a) and ibuprofen recrystallized in ethanol (spectrum in Figure
4b). Inset shows carbonyl region of ibuprofen spectra (normalized)
clearly indicating the shift in frequency of ibuprofen/HA complex to
higher wavenumbers (1717 cm−1), compared to pure ibuprofen (1707
cm−1).
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expressed in molar fraction, with the condition PM + PD = 1.
Initial estimates for δM and δD were used to evaluate PD
iteratively (full details are given in the Supporting Information
(Figures S7−S13).
By using this approach, a Keq,D,CDCl3 value of [D]/[M]
2 = 116
was determined, thus showing the existence of large amounts of
a dimer in solution. We consider this value to be an upper limit,
with respect to the same equilibrium in ethanol. In fact, because
of competing line broadening for the proton on COOH with
the OH group of ethanol, it is not possible to extract this
information directly in ethanol solutions. On the other hand, by
using this same approach, it is possible to provide a crude
estimate for the value of equilibrium constant for the process M
+ EtOH → M/EtOH via analysis of the shift of ethanol signal
in ibuprofen-containing solutions. By using the same approach
on peak position analysis, with δm = δEtOHPEtOH +
δM/EtOHPM/EtOH a rough estimate of Keq,EtOD = [M/EtOH]/
([M]•[EtOH]) = 0.8 was obtained, thus showing the existence
of both monomer and dimer in solution.
Therefore, having assessed the presence of ibuprofen
monomer in the ethanol solution, the next step was to evaluate
the presence of dimer, monomer, and possible adsorbed
species, in the ibuprofen/HA complex that we synthesized,
using time-online IR spectroscopic measurements. An in situ
experiment was carried out, using an as-prepared ibuprofen/HA
complex specimen that was transferred directly from the
preparation ﬂask onto the ATR crystal of the spectrometer.
Measurements were taken at various time points (from 6 min
to 180 min) and we did not observe any peak at 1717 cm−1 (as
in Figure 4 above), a band that we believe corresponds to the
adsorbed monomeric ibuprofen species.
To investigate this phenomenon, we performed ex situ
measurements where the specimens were taken from the
preparation ﬂask at given time points and transferred onto the
ATR crystal instead (Figure 5).
This is diﬀerent from the previous, in situ, IR experiment,
because, in the ﬁrst case, the specimen is always the same across
the experiment, whereas, in this second case, the specimens are
diﬀerent at every measurement time point, although still
originating from the same ibuprofen/HA sample (ﬂask).
Interestingly, in the case of ex situ kinetic studies, we were
able to observe a peak at 1717 cm−1 instead. This suggests that
keeping a specimen between the force applicator and the ATR
crystal for the entire duration of the in situ experiment (180
min) prevents the formation of the adsorbed species, leading
only to the recrystallization of the ibuprofen dimer.
3.4. Mechanistic Studies and Molecular Modeling. The
data gathered using ex situ time-online infrared studies for the
ibuprofen/HA complex prompted us to investigate and
describe a possible mechanism for the intermolecular complex
formation by using a combination of computational studies, as
well as FTIR and Raman spectroscopies.
Computational studies were carried out using density
functional theory and a B3LYP functional, using 6-311G(d,p)
basis set for all other atoms. Our model considers the
energetics of an ibuprofen monomer versus a more stable
dimeric species and the interaction that this monomer can have
with an HA adsorption site.
3.4.1. Energetics and Structures of Ibuprofen Monomer
and Dimer. Ibuprofen is a molecule that can exist in several
conformers. By using a B3LYP/6-31G(d) level of theory, De
Cararvalho and co-workers identiﬁed eight stable minima.46 Of
these conformers, the most stable and the one best matching IR
data was a structure presenting the carboxyl and isobutyl groups
of the ibuprofen molecule on opposite sides, with respect to the
plane of the benzene ring. Employing this structural element as
a starting point, we optimized this structure using a higher level
of theory for structure optimization (B3LYP/6-311G(d,p)),
and obtained the structure reported in Figures 6a and 6b. This
has been used as a model for the formation of an ibuprofen
dimer, as well as ibuprofen/HA interactions in our study.
For completeness, we should mention that we identiﬁed a
further minimum (Figures 6c and 6d) close in energy to the
previous one, with an energy gap of +15 kJ mol−1. This energy
gap is reasonably small and the two species might both exist in
Figure 5. Kinetics of the ibuprofen/HA complex formation, ex situ
ATR-FTIR measurements of the carbonyl region of ibuprofen between
6 and 180 min, showing the evolution of the peak assigned as attached
species, and the signal decay of the dimer and monomer peaks.
Figure 6. Ibuprofen structure optimized using a DFT/B3LYP/6-
311G(d,p) level of theory: (a and b) absolute minimum with (a)
ibuprofen view from top highlighting the carboxyl group, and (b)
ibuprofen view from side to highlight the relative position of carbonyl
and isopropyl groups with respect to the benzene ring. (c and d)
relative minimum for a conformer obtained by rotation of the carbonyl
group along a C−C axis from structure (a). For this second structure:
(c) view from top highlighting the rotation of the carbonyl group, and
(d) view from a side with respect to the benzene ring plane. Note the
orientation of the hydroxyl group with the H atom pointing to the
benzene ring, underlying an intramolecular hydrogen bond. Color
code: (red atoms) oxygen, (gray atoms) carbon, (white atoms)
hydrogen.
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solution. We think this second minimum exists by virtue of an
intramolecular hydrogen bond between the H atom of the
hydroxyl group and the benzene ring48 (Figure 6d). However,
since this conformer is less stable, and it would not be able to
form a dimer, because of the orientation of the hydroxyl group
pointing to the benzene ring, it will not be considered further in
our discussion.
Using the conformer in Figures 6a and 6b, we ﬁrst
determined the structure of an ibuprofen dimer. In principle,
two dimeric forms can be postulated: a cis form, with the
carbon skeletons of the two ibuprofen molecules facing each
other, or a trans form, where the carbon skeletons of the two
molecules are in the opposite direction, with respect to the
plane identiﬁed by the carboxylic groups of ibuprofen. In this
study, only the trans dimer has been considered as it is the most
stable and its existence has been proved in the solid state.18
Using our model, the trans dimer (Figure S14 in the Supporting
Information) has a stabilization energy, with respect to two
isolated molecules of ibuprofen, of −69 kJ mol−1. This indicates
a strong hydrogen-bond interaction between the OH and CO
groups of the carboxyl unit of a molecule of ibuprofen with the
CO and OH groups, respectively, of another molecule of
ibuprofen (see Figure S14).
Conversely, it also shows that the process of dissociation of a
dimer to two units of monomer is not spontaneous. However,
as in our experiments, ibuprofen is dissolved in ethanol, and we
detected the existence of an IR band at 1735 cm−1 (see section
3.3) when both ibuprofen and ethanol are present, we can
assume that this solvent promotes the dimer dissociation into
two monomer units. That is the formation of an ibuprofen/
ethanol complex in solution via the reaction: D + 2EtOH →
2M/EtOH (where D and M stand for dimer and monomer,
respectively). A stable hydrogen-bonded M/EtOH complex
was identiﬁed (Figure S15 in the Supporting Information) and
the energetics of this dissociation reaction assisted by ethanol
was calculated to be −29 kJ mol−1 and thus favored.
Note that our IR data identify a peak at 1735 cm−1 that is
observed in the presence of ethanol only. With our data, we
think that we can assign this peak to an ibuprofen/ethanol
complex, as expected in the dissolution process.
3.4.2. Hydroxyapatite (HA) Adsorption Site. In order to
mimic hydroxyapatite and ibuprofen interaction, an adsorption
site was built. This site was constructed by using a simpliﬁed,
yet useful, model comprising the most distinct features of HA
in place of an entire hydroxyapatite crystal. These features are
the presence of a phosphate group bound to a calcium atom
presenting two hydroxyl groups (Figure S16 in the Supporting
Information).
In order to validate whether this neutral HA fragment is
representative for our studies, we calculated the position of IR
bands for stretching and bending motions of the phosphate
group, and for the libration motion of the OH groups (which
are also bound to a single Ca center in a HA crystal). Our
model calculates these vibrations at 1036, 411, and 608 cm−1,
respectively. Experimental values for these same vibrations are
1020, 443, and 632 cm−1.49 Taking into account that our
simpliﬁed model does not include lattice parameters, the
calculated wavenumber values are in good agreement with
experimental data, and, as such, we consider it to be a good
platform for the investigation of ibuprofen and HA interactions.
3.4.3. Ibuprofen and Hydroxyapatite (HA) Interactions.
From the ibuprofen and HA structures described in sections
3.4.1 and 3.4.2 (and Figures 6 and Figure S16), an adsorption
complex between ibuprofen and HA was built. A stable
minimum with a large stabilization energy of −133 kJ mol−1
was found (see Figure S17 in the Supporting Information).
This minimum presents a hydrogen bond interaction
between ibuprofen and HA. However, and quite interestingly,
this hydrogen-bond interaction occurs between the OH group
of the carboxyl function of ibuprofen (HOibuprofen) and the
hydroxyl groups of the HA bound to Ca (HOapatite) in a
HOapatite···HOibuprofen interaction. That is, this bond does not
involve a hydrogen bond between the CO group of ibuprofen
(COibuprofen) and the OH group of the hydroxyapatite
(HOapatite) in a COibuprofen···HOapatite interaction, but the
carbonyl group appears to interact with the apatite via a Ca
center, as a COibuprofen···Caapatite instead. As such, two anchoring
points for ibuprofen are present via HOapatite and Caapatite
centers.
In the other words, a hydrogen bond is present and, as such,
ﬁts current tentative explanations of ibuprofen and HA
interactions;23 however, in our case, this is an HOapatite···
HOibuprofen hydrogen-bond interaction, and not a COibuprofen···
HOapatite hydrogen-bond interaction.
23 Furthermore, our model
also suggests that changes in vibrational frequencies of the C
O group of ibuprofen are also due to the existence of a non-
hydrogen-bond, COibuprofen···Caapatite interaction.
For this complex, we calculated a CO vibrational
frequency of 1694 cm−1. This correctly predicts a red shift of
∼50 cm−1, with respect to an isolated monomeric species
(expected at 1746 cm−1). However, our level of theory does not
allow an unambiguous assignment of IR bands from the spectra
as the dimer is also calculated in the 1694 cm−1 region.
however, in this context, it is worth noting that such an
interaction is not unusual between a carboxyl group and a metal
center and it has been observed in the case of species
containing Zn,50 where the carboxyl group binds via the
carbonyl unit in a monodentate manner, and it also might be
operating in our case.
Raman scattering is sensitive to changes in polarizability51
and, therefore, has diﬀerent selection rules, compared to IR
absorption, and the two techniques can complement each
other. For this speciﬁc case, we applied Raman spectroscopy to
have a wide splitting between the Raman active symmetric C
O stretching frequency of the dimer, and the CO stretching
vibration of the adsorbed species. The CO stretching
vibrations of the dimer split into the symmetric, Raman-active
vibration at lower wavenumber, and the antisymmetric, IR
active vibration at higher wavenumber. Whereas in the IR
spectrum, the antisymmetric CO stretching of the dimer
partially overlaps with the CO stretching vibration of the
adsorbed monomer, in the Raman spectrum, the vibrations are
much more separated, making an assignment and interpretation
less ambiguous. Raman spectra for pure ibuprofen, ibuprofen in
the presence of ethanol, and a sample from an ibuprofen,
ethanol, and HA mixture after drying, are reported in Figure 7.
The most intense peak of this set of spectra is centered at ca.
1610 cm−1 and corresponds to the vibration of the C−C bond
of the benzyl ring. The weaker peak at 1652 cm−1 in the
spectrum in Figure 7a corresponds to the symmetric CO
stretching vibration of an ibuprofen dimer.52 The presence of
this peak must be expected in a sample of pure ibuprofen
(Figure 7a), because the dimer is the most stable species in
solid form (vide supra).
When some ethanol is added to the sample (Figure 7b), the
1652 cm−1 dimer band disappears and a new and broad peak in
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the region 1700−1730 cm−1 appears. We ascribe this signal to a
CO stretching vibration of monomer ibuprofen aﬀected by
hydrogen bonding with ethanol. In the case of the ibuprofen/
HA complex sample (Figure 7c), we can note the presence of a
sharper peak at ca. 1710 cm−1 that we assign to CO
stretching of an ibuprofen monomer adsorbed to HA, possibly
via a CO···Ca interaction, as described above. In this
spectrum, the dimer peak at 1652 cm−1 has disappeared,
showing that, in this sample, ibuprofen is likely not in the dimer
conﬁguration anymore, but mainly bonded to HA. The small
but signiﬁcant shift of the C−C stretching at 1610 cm−1 moving
from the spectrum in Figure 7a to the spectra in Figures 7b and
7c, reﬂects a change from a dimer to a monomer.
Considering these assignments, a summary of the stabiliza-
tion energies of ibuprofen, with respect to dimer, monomer/
EtOH, and monomer/HA, which will be useful for our
reasoning for the next sections, is reported below (see Figure
8, as well as Table S1 in the Supporting Information).
From the energy diagram, it is possible to observe that any
interaction of the monomer with another monomer, ethanol, or
HA is always a favorable process. However, the most
energetically stable interaction is the one between a monomer
of ibuprofen and hydroxyapatite, thus suggesting the formation
of an adsorbed species. In addition, the formation of an
ibuprofen/ethanol complex is also favored, with respect to the
formation of an ibuprofen dimer from two independent
monomeric units, and thus supporting a dissolution process
and the formation of a monomer under our conditions, as
detected in IR (Figure S5 and at 1735 cm−1), and, importantly,
the disappearance at 1652 cm−1 from Raman spectra (from a
dimer) when ethanol is added (Figure 7b) and the formation of
a new band in the region of 1700−1730 cm−1.
3.4.4. Kinetics of the Adsorption of Ibuprofen to the
Surface of Hydroxyapatite. Having ascertained the presence of
an adsorbed ibuprofen species to HA, and with this species
possibly presenting a hydrogen bond HOapatiteCHOibuprofen, and
a COibuprofen···Caapatite interaction, we carried out a kinetic study
in order to gain an in-depth knowledge of the adsorption
process.
From the spectra reported in section 3.3, it is possible to
observe a decay of the signal for a M/EtOH species, an increase
of an adsorbed ibuprofen species on the HA surface, here
denoted M/HA, and an almost-constant signal for the
ibuprofen in dimeric form, denoted here as D. The signal
intensities are reported in Figure 9.
The almost-constant signal for the bulk ibuprofen dimer D
can be easily explained with the working principle of the ATR-
FTIR method (see section 3.1).36 This technique is often
referred as a surface method, but with a penetration depth of a
few micrometers. Therefore, with respect to ibuprofen present
Figure 7. Raman spectra of (a) pure ibuprofen powder, (b)
ibuprofen−ethanol solution, and (c) ibuprofen-loaded H-apatite
(dry). The most intense band at ca. 1610 cm−1, observed in all
spectra, is a C−C stretching vibration of the aryl ring. The band at
1652 cm−1 observed in spectrum (a) is the symmetric stretching of the
CO bond in the dimer. The broad band in the region 1700−1730
cm−1 in spectrum (b) is for a CO stretching of ibuprofen in an
ibuprofen/ethanol complex. The band at 1710 cm−1 for spectrum (c)
arises from the CO stretching of ibuprofen in an ibuprofen/HA
complex.
Figure 8. Energy diagram summarizing the stabilization energies for
dimer or complexes formation from a monomer of ibuprofen. The
symbol “+” stands for two isolated molecules or fragments, the symbol
“/” stands for a complex formation. M = ibuprofen monomer, D =
dimer, EtOH = ethanol, and HA = hydroxyapatite.
Figure 9. Signal intensity evolution (from ATR-FTIR) against time for
(red circles, −●−) ibuprofen monomer (vide inf ra), (black squares,
−■−) ibuprofen dimer, and (green triangles, −▲−) monomer
adsorbed over HA surface.
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in layers such as M/EtOH or M/HA, the ibuprofen presenting
a dimer D appears in large excess, and therefore no change in
its intensity occurs.
A M/EtOH complex can form an adsorbed species or evolve
to a dimer. The energetics for these processes are reported here
(per molecule of ibuprofen), in eqs 1 and 2.
+ → +
Δ = − −E
M/EtOH HA M/HA EtOH
84 kJ mol 1 (1)
× → + × Δ = + −E2 M/EtOH D 2 EtOH 29 kJ mol 1
(2)
Note that if ethanol is taken into account in the process,
whereas the adsorption of an ibuprofen molecule is a favorable
process (eqs 1 and 2), the formation of a dimer in the presence
of ethanol (eq 2) is now an unfavorable process, presenting a
small, yet positive, ΔE value (+29 kJ mol−1). This was not the
case if the dimer formation was considered without the
presence of ethanol (see section 3.4.1), where a stabilization
energy of −69 kJ mol−1 was calculated instead.
As a consequence, these data would suggest that the increase
in signal that we observe in the spectra in Figure 5 is due to a
process involving the evolution of a M/EtOH species to an
adsorbed one, M/HA, which is a process now favored, with
respect to the formation of a dimer.
In order to experimentally discriminate between the
evolution of a monomer M or M/EtOH species to an adsorbed
Mads or M/HA against a dimeric species D, we applied a
kinetic analysis to the signal decay. In fact, for a monomer that
evolves to an adsorbed species, either M→Mads or M/EtOH +
HA → M/HA + EtOH, this would imply a ﬁrst-order decay of
signal I of M/EtOH and a kinetics equal to
= −I I et kt0 (3)
where It is the intensity of the IR signal (absorbance) at time t,
k the kinetic constant of the decay process, and I0 the intensity
of the signal at the start of the measurement.
If the monomer M or M/EtOH evolves to a dimer (D = 2M)
instead (or 2 × M/EtOH → D + 2EtOH), this implies the
consumption of two molecules of monomer (2M→ D) and, in
turn, a second-order kinetics instead. In this case, the process is
described by the equation:
=
+
I
I
ktI1t
0
0 (4)
Both these models were used to ﬁt the signal decay of the
monomeric species (Figure S18 in the Supporting Informa-
tion). It is possible to observe that a ﬁrst-order kinetics (Figure
S18a) ﬁts the data well for the decay of the monomeric species,
unlike a second-order model (Figure S18b), with values of R2 =
0.985 and 0.894, respectively. We can then conclude that, based
on both calculated stability and ﬁtted kinetics, the decay of
signal from the monomeric species M/EtOH is consistent with
its evolution to an adsorbed species over the HA surface: M→
Mads, for a process: M/EtOH + HA → M/HA + EtOH.
The same principle has been applied for the growth of the
signal of the adsorbed species. From the raw data (Figure 9), it
also appears that the bare growth of the adsorbed species is 2−
3 times greater than the decay of the monomeric species.
However, since the signal is related to the absorbance A by the
Beer−Lambert law,
ε=A bc
the signal is also a function of the intrinsic extinction coeﬃcient
(ε). By using our level of theory, the stretching of the carbonyl
group for an adsorbed species is ∼2 times more intense than
the intensity of the signal for an isolated monomer. If we apply
this as a correction factor to the growth of the adsorbed species,
the kinetics of the growth for the adsorbed species is almost
identical to the kinetics of decay of the monomer (see Figure
S18).
In order to further corroborate these data, we estimated the
equilibrium constant Keq,Ads for the process Mads → Mads, by
analyzing the decay of the free monomer and the growth of the
adsorbed species. We estimated a value of Keq,Ads = [Mads]/
[Mads] = 39. Note that this value is in the same order of
magnitude as the estimated equilibrium constant for the dimer
formation in ethanol. We think this is another factor that
contributes to our capability to detect and monitor the
evolution of a free ibuprofen species to an attached species
over the HA surface.
In summary, the adsorption process of an ibuprofen
molecule to a site on HA can be schematized as follows:
+ → × Δ = − −ED 2EtOH 2 M/EtOH 29 kJ mol 1
(5)
× + → +
Δ = × − = −− −E
2 (M/EtOH HA M/HA EtOH)
2 ( 84 kJ mol ) 168 kJ mol1 1 (6)
Net equation:
+ → × Δ = − −ED 2HA 2 M/HA 197 kJ mol 1 (7)
That is, the adsorption of a monomeric ibuprofen species to
an adsorption site of HA is a largely energetically favorable
process that occurs in two steps: the dissociation of the
ibuprofen dimer to a monomer mediated by ethanol, and the
adsorption process to the HA surface via ﬁrst-order kinetics.
3.5. Dissolution Studies. Finally, we decided to verify how
the adsorption of ibuprofen on the surface of hydroxyapatite
will inﬂuence the drug release properties. Figure 10 shows the
drug release proﬁles of pure ibuprofen (as a control), a physical
mixture of ibuprofen and HA, and ibuprofen/HA complex that
we proved to be made of a hydrogen bonded API monomer
weakly attached to the surface of HA. Figure 10 demonstrates
that the drug release of physical mixture is similar to that of a
pure ibuprofen, whereas the drug release rate for the ibuprofen/
HA complex is statistically slower at the initial time points
(between 5 and 180 min) but then equalizes by the 4 h
measurement. There have been some reports studying the
correlation between the structure and/or porosity of HA versus
ibuprofen release.23,24 In these studies, the porosity of the
system signiﬁcantly increases the drug retention time, whereas,
in our case, we observe only a slight delay in the drug release
during the ﬁrst hour. This could possibly be explained by the
fact that the main cause of the retardation of ibuprofen release
is due to weak intermolecular bonding between the API and the
carrier, and not the geometry of the HA. The intense drug
release at the early time points of the dissolution is normally
associated with the concentration gradients on the surface,
where diﬀusion pathways are short, followed by the decrease of
the drug release rate due to the increase in the diﬀusion
pathways from the bulk. Such formulations are referred to as
diﬀusion-controlled drug delivery system, and the kinetics is
based on the known cylindrical geometry of the tablets and
Langmuir Article
DOI: 10.1021/acs.langmuir.6b04510
Langmuir 2017, 33, 2965−2976
2973
Fick’s second law of diﬀusion.24 In our case, however, we did
not produce tablets, and therefore ibuprofen that formed a thin
layer on the surface of the HA powder is readily released mostly
from the surface rather than the bulk, thus suggesting that the
proﬁle observed in Figure 10 is not fully diﬀusion-controlled.
We relate this slower, and desirable, drug release to the
adsorption of the API, compared to the biphasic physical
mixture where the two components are not bonded to each
other, thus proving that the intramolecular bonding eﬀect
between the API and a carrier is an important factor when
designing materials with controlled drug release properties. The
majority of the studies on combining ceramics and anti-
inﬂammatories concentrate their attention on prolonged drug
release, whereas for the treatment of arthritic patients, a “burst”
drug release may be required at a point of need, followed by a
prolonged drug release afterward.53 Our study suggests that
when ibuprofen and HA form a hydrogen-bonded complex, it
may be more diﬃcult to obtain an immediate release due to an
API-carrier interaction, in turn impeding design of materials
with dual properties when using the method of dissolving and
recrystallizing drug in the presence of a ceramic carrier.
4. CONCLUSIONS
In this study, we elucidated the mechanism of the ibuprofen
adsorption onto the surface of nanohydroxyapatite and its
eﬀects on the drug dissolution rate, explaining earlier ﬁndings
on the shift of the FTIR signal of the carbonyl group of the API
in the presence of ceramics. Herein, using an array of
characterization tools, we demonstrated that, when synthesizing
an ibuprofen/ceramic complex, hydrogen bonding occurs
between the carbonyl group of the API and a Ca center of
hydroxyapatite (HA). The process of surface attachment
follows the steps: (i) ibuprofen dimer partial dissolution in a
solvent, (ii) formation of a monomer/solvent complex from a
dimer, and (iii) subsequent preferential attachment of the
ibuprofen monomer to the hydroxyapatite. The latter is
represented by a hydrogen bond between the hydroxyl group
of ibuprofen and one of the hydroxyl groups of the HA, along
with an interaction between the carbonyl group of ibuprofen
and a Ca center of HA. The formation of this complex occurs
by means of ﬁrst-order kinetics.
Furthermore, we have also demonstrated the inﬂuence of
such noncovalent bonding on the release/dissolution rate of the
drug. Through investigation of the behavior of the intra-
molecularly bonded ibuprofen−HA system under physiological
conditions (phosphate buﬀer) and comparing it with the
biphasic mixture of the two components, we have shown that
the initial API release rate from the complex is inﬂuenced by
the hydrogen-bonding-induced attachment of the ibuprofen to
the surface of nanohydroxyapatite. On a wider perspective, we
believe the results of this work will help to understand the eﬀect
of hydrogen bonding on the attachment of the APIs to the
surface of the drug carrier and its contribution to the
dissolution proﬁle of the system.
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Peŕez, M. S. Conformational analysis of some α-phenylpropionic acids
with anti-inflammatory activity. J. Pharm. Sci. 1985, 74, 47−49.
(20) Kierys, A.; Grochowicz, M.; Kosik, P. Fabrication of porous
hollow γ-Al2O3 nanofibers by facile electrospinning and its application
for water remediation. Microporous Mesoporous Mater. 2015, 217, 133−
140.
(21) Qi, C.; Zhu, Y.-J.; Lu, B.-Q.; Zhao, X.-Y.; Zhao, J.; Chen, F.
Hydroxyapatite nanosheet-assembled porous hollow microspheres:
DNA-templated hydrothermal synthesis, drug delivery and protein
adsorption. J. Mater. Chem. 2012, 22, 22642−22650.
(22) Melville, A. J.; Rodríguez-Lorenzo, L. M.; Forsythe, J. S. Effects
of calcination temperature on the drug delivery behaviour of Ibuprofen
from hydroxyapatite powders. J. Mater. Sci.: Mater. Med. 2008, 19,
1187−1195.
(23) Sambudi, N. S.; Chob, S.; Cho, K. Porous hollow hydroxyapatite
microspheres synthesized by spray pyrolysis using a microalga
template: Preparation, drug delivery, and bioactivity. RSC Adv. 2016,
6, 43041−43048.
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